You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 1, 2024

IDOSE TR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Idose Tr patents expire, and when can generic versions of Idose Tr launch?

Idose Tr is a drug marketed by Glaukos and is included in one NDA. There are two patents protecting this drug.

This drug has fifty patent family members in seven countries.

The generic ingredient in IDOSE TR is travoprost. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Idose Tr

A generic version of IDOSE TR was approved as travoprost by CHARTWELL RX on March 1st, 2013.

  Try a Trial

Summary for IDOSE TR
International Patents:50
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for IDOSE TR
What excipients (inactive ingredients) are in IDOSE TR?IDOSE TR excipients list
DailyMed Link:IDOSE TR at DailyMed
Drug patent expirations by year for IDOSE TR
Drug Prices for IDOSE TR

See drug prices for IDOSE TR

Pharmacology for IDOSE TR

US Patents and Regulatory Information for IDOSE TR

IDOSE TR is protected by two US patents and one FDA Regulatory Exclusivity.

Patents protecting IDOSE TR

Implants with controlled drug delivery features and methods of using same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Implants with controlled drug delivery features and methods of using same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting IDOSE TR

NEW PRODUCT
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaukos IDOSE TR travoprost IMPLANT;INTRACAMERAL 218010-001 Dec 13, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Glaukos IDOSE TR travoprost IMPLANT;INTRACAMERAL 218010-001 Dec 13, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Glaukos IDOSE TR travoprost IMPLANT;INTRACAMERAL 218010-001 Dec 13, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for IDOSE TR

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Novartis Europharm Limited Izba travoprost EMEA/H/C/002738
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.
Authorised no no no 2014-02-20
Novartis Europharm Limited Travatan travoprost EMEA/H/C/000390
Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).
Authorised no no no 2001-11-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for IDOSE TR

See the table below for patents covering IDOSE TR around the world.

Country Patent Number Title Estimated Expiration
Japan 2017047262 薬剤溶出眼内インプラント (DRUG ELUTING OCULAR IMPLANT) ⤷  Try a Trial
European Patent Office 3603590 IMPLANTS AYANT DES CARACTÉRISTIQUES D'ADMINISTRATION DE MÉDICAMENTS CONTRÔLÉE (IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES) ⤷  Try a Trial
Japan 6714674 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for IDOSE TR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1920764 C300540 Netherlands ⤷  Try a Trial PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
1920764 SPC/GB12/038 United Kingdom ⤷  Try a Trial PRODUCT NAME: TRAVOPROST; REGISTERED: UK EU/1/01/199/001-002 20011129
1920764 2012/033 Ireland ⤷  Try a Trial PRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.